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 2010 Wiley-LissABSTRACT: An important attribute of cocrystals is that their properties can be tailored to meet
required solubility and stability specifications. But before such practical uses can be realized, a
better understanding of the factors that dictate cocrystal behavior is needed. This study
attempts to explain the phase behavior of anhydrous/hydrated cocrystals when the coformer
modulates both water activity and cocrystal solubility. Stability dependence on solution com-
position and water activity was studied for theophylline–citric acid (THP–CTA) anhydrous and
hydrated cocrystals by both suspension and vapor equilibration methods. Eutectic points and
associated water activities were measured by suspension equilibration methods to determine
stability regions and phase diagrams. The critical water activity for the anhydrous–hydrate
cocrystal was found to be 0.8. It is shown that (a) both water and coformer activities determine
phase stability, and (b) excipients that alter water activity can profoundly affect the hydrate/
anhydrous eutectic points and phase stability. Vapor phase stability studies demonstrate that
cocrystals of highly water soluble coformers, such as citric acid, are predisposed to conversions
due to moisture uptake and deliquescence of the coformer. The presence of such coformers as
trace level impurities with cocrystal will alter hygroscopic behavior and stability.  2010 Wiley-
Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:3977–3985, 2010Keywords: hygroscopicity; transition concentration; eutectic point; phase diagram; stabilityINTRODUCTION
The ability of cocrystals to increase drug thermo-
dynamic activity,1–4 which may translate to improved
bioavailability for poorly water soluble drugs, has
deepened our awareness of solid phase stability
during processing, storage, and dissolution.5–7
Cocrystals can exist as anhydrous and hydrated
forms and convert to (a) hydrated or anhydrous
components, in addition to (b) hydrated or anhydrous
cocrystal.4,8–12 For this reason, stability issues of
cocrystals will be more challenging than those of its
associated component crystals.
While the phase behavior of pharmaceutical
hydrates is well established3,13–19 that of cocrystal
hydrates is not. In the case of pharmaceutical
hydrates, conversion to hydrate or anhydrous phases
is mainly determined by the water activity, aw, of the
surrounding medium (vapor or liquid phase).13,14,20–23yasankar’s present address is Global Formulation
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JOURNAL OFCocrystals however can follow different transforma-
tion pathways depending on the purity of the
cocrystal phase and solution compositions.9,10,24–28
Thus, both water and solute activities are expected to
play an important role on the stability of cocrystal
phases.
Cocrystals not only alter aqueous solubility but also
enable a wide range of solubility behaviors based on
coformer selection, and in this way solve drug
delivery problems.1,4,7 Hence, the advantages out-
weigh the perceived stability challenges. Drugs, such
as carbamazepine (CBZ), theophylline, and caffeine,
that exist as both anhydrous and hydrated crystals,
form anhydrous cocrystals with several cofor-
mers.8,24,25,29,30 Some of these cocrystals have been
shown to improve resistance to hydration although
their component crystal phases are prone to hydra-
tion or to deliquescence (e.g., nicotinamide, maleic,
malonic, citric acid (CTA), and other carboxylic
acids).8,11,31 A few cocrystals are also reported to
form both anhydrous and hydrated phases,12,24,32 yet
the factors that control their formation and stability
in solvents are not well known.
This report attempts to explain the transformation
pathways of cocrystal anhydrous/hydrates when
coformer modulates both aw and cocrystal solubility.PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 2010 3977
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composition and aw for theophylline–citric acid
(THP–CTA) anhydrous and hydrated cocrystals.
CTA is very water soluble (8.37 m at 258C)33,34 and
deliquescent, with saturation aw of 0.78–0.79 or
deliquescence relative humidity (DRH) of 78–79%
at 258C.33–35 The THP–CTA cocrystal-solution phase
diagram was generated from eutectic point measure-
ments where two solid phases coexist in equilibrium
with solution. Water activities at eutectic points were
measured and related to the stability of the anhy-
drous/hydrated cocrystal phases in solutions of
varying aw and in vapor phase in a range of RH.
Additives used in pharmaceutical formulations can
also lower aw and to this effect the cocrystal hydrate/
anhydrous stability and associated eutectic point
were assessed in solutions of fructose. Since CTA is
deliquescent, the RH-dependent transformation
pathways of binary mixtures of cocrystal components
were investigated, and are explained by the solution-
phase behavior of cocrystal and its components.
Finally, the stability of carbamazepine–4 amino
benzoic acid (CBZ–4ABA) hydrate/anhydrous as a
function of aw was measured. As with THP–CTA, this
cocrystal is more soluble than the drug and converts
to CBZ dihydrate when suspended in water.4 How-
ever, the coformer in this case, 4ABA, has low-
aqueous solubility 36 and is less effective in lowering
aw. These findings have significant implications for
determining the factors that control cocrystal stabi-
lity and conversions. Furthermore, since the phase at
equilibrium is determined by solution composition
and ambient water activity, the purity of cocrystal
phase will greatly affect stability.EXPERIMENTAL
Materials
Anhydrous THP form (II), anhydrous CBZ form (III),
and 4-aminobenzoic acid (4ABA) form (a) used in the
studies were purchased from Sigma–Aldrich, St.
Louis, MO. Anhydrous CTA was purchased from
Fisher Scientific, NJ. All chemicals were character-
ized by X-ray powder diffraction (XRPD) and Raman
spectroscopy prior to use. Ethanol and 2-acetonitrile,
purchased from Acros, NJ, were dried using mole-
cular sieves prior to use.
Cocrystal Synthesis
Cocrystals were prepared by the reaction crystal-
lization method at room temperature by adding drug
to nonstoichiometric solutions of coformer.27,37 Anhy-
drous THP–CTA (1:1) and CBZ–4ABA (2:1) cocrystals
were prepared in ethanol. THP–CTA hydrate (1:1:1)
and CBZ–4ABA hydrate (2:1:1) cocrystals wereJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 2010prepared in water. Solid phases were isolated and
characterized by XRPD and Raman spectroscopy.
Suspension Equilibration Studies
THP–CTA hydrate stability dependence on coformer
solution concentration was examined by suspending
excess cocrystal hydrate in aqueous solutions with
varying CTA concentrations. The suspensions were
magnetically stirred in a water bath at 25.0 0.58C
for 24–48 h prior to adding anhydrous cocrystal. The
suspensions were stirred for 2–3 weeks to reach
equilibrium. Solution concentrations of CTA at
equilibrium were measured by HPLC. Equilibrium
was considered to be achieved when the solution
concentrations did not change by more than 2–3%.
Solid phases were characterized by Raman spectro-
scopy and XRPD. The water activities of the
equilibrated suspensions were determined by mea-
suring the RH above the suspensions using a
Hydroclip RH probe from Rotronics (Huntington,
NY). Probe accuracy is 1.5% RH/0.28C.
THP–CTA hydrate stability dependence on water
activity was studied by suspending excess THP–CTA
hydrate in aqueous fructose–CTA solutions with
varying fructose concentration but constant CTA
concentration (6.05 m) at 25.0 0.58C. The suspen-
sions were allowed to reach equilibrium as described
above. Solid phase stability in suspensions was
periodically monitored using Raman spectroscopy
and XRPD. The water activity of the suspensions was
determined by measuring the RH as described above.
CBZ–4ABA hydrate stability dependence on water
activity was studied in water/acetonitrile solutions
since the anhydrous cocrystal was stable in acetoni-
trile. Solutions of water and acetronitrile ranging
from mole fraction of water (xw) 0 to 0.054 with water
activities between 0 and 0.41 were prepared based on
literature values.38 The suspensions were magneti-
cally stirred for 48 h at 25.0 0.58C prior to adding
anhydrous cocrystal. The suspensions were then
stirred for an additional 2 weeks. Solid phases were
characterized by Raman spectroscopy and XRPD to
monitor phase transformations.
Eutectic Concentration Measurement
Three eutectic points were examined for the THP–
CTA cocrystal in water where the following phases
coexist in equilibrium with solution: eutectic (E1)
THP hydrate and cocrystal hydrate, eutectic (E2)
cocrystal hydrate and anhydrous cocrystal, and
eutectic (E3) anhydrous cocrystal and CTA monohy-
drate. Eutectic concentrations of THP and CTA were
measured by HPLC after equilibrating the two solid
phases (as indicated for E1, E2, and E3) with aqueous
solutions at 25.0 0.58C. Equilibrium was considered
to be achieved when solution concentrations reached
a constant value while two solid phases coexist. TheDOI 10.1002/jps
TRANSFORMATION PATHWAYS OF COCRYSTAL HYDRATES 3979solid phases in suspension were initially character-
ized by Raman spectroscopy. The suspensions were
filtered and the solid phases were characterized by
XRPD. Water activities corresponding to the eutectic
concentrations were determined by measuring the
RH above the equilibrated suspensions as described
above.
RH-Dependent Solid Phase Stability
Cocrystal
The moisture uptake and stability of THP–CTA and
CBZ–4ABA cocrystals (anhydrous and hydrated) was
examined at several RH values. THP–CTA (1:1) and
THP–CTA hydrate (1:1:1) were studied at 85% and
98% RH at 25.0 0.58C. CBZ–4ABA (2:1) and CBZ–
4ABA hydrate (2:1:1) were studied at 0%, 13%, 43%,
and 89% RH at room temperature (24 18C). Desired
RH conditions were achieved in sealed desiccators
containing the appropriate saturated salt solution:
P2O5 (0%), LiClH2O (13%), K2CO32H2O (43%), NaCl
(75%), KCl (85%), BaCl22H2O (89%), and K2SO4
(98%).39,40 Samples (30–60 mg, 45–63mm) were ana-
lyzed by XRPD prior to and after exposure to the
different RH conditions.
Mixtures of Cocrystal Components
The role of moisture uptake on cocrystal formation in
equimolar mixtures (30–60 mg, 45–63mm) of anhy-
drous THP and anhydrous CTA was studied in
desiccators equilibrated to 75%, 85%, and 98% RH
at 25.0 0.58C using the procedures described in an
earlier study.41 Mixtures were analyzed by XRPD
prior to introduction into desiccators. Phase trans-
formations in closed desiccators were monitored by
Raman spectroscopy. Spectra were collected fre-
quently over random areas of the sample for several
days. HoloReact software, from Kaiser Optical
Systems (Ann Arbor, MI), was used for multivariate
curve resolution to plot the change in spectral
features correlating to reactants and cocrystal. The
analysis region for the THP–CTA systems was 1600–
1750 cm1. Change in spectral features over time was
used to monitor cocrystal formation. Samples were
promptly analyzed by XRPD once removed from the
desiccator.
Raman Spectroscopy
Raman spectra of solid phases were collected with an
RXN1 Raman spectrometer equipped with a 785 nm
laser from Kaiser Optical System, Inc. Solid phase
transformation in samples was monitored using an
immersion or noncontact fiber optic probe. The
immersion probe was used to collect the spectra of
solid phases in aqueous suspensions and the non-
contact probe was used to monitor transformations in
solid mixtures during storage. Acquisition conditionsDOI 10.1002/jps JOwere optimized so that the spectra collected had
maximum intensity (30–40 k). The spectra were
collected between 100 and 1800 cm1 with a resolu-
tion of 4 cm1.
X-Ray Powder Diffraction
XRPD was used to identify solid phases recovered
from the suspension equilibration studies, eutectic
measurements, and the vapor phase equilibration
studies. XRPD patterns of solid phases were recorded
with a Rigaku Miniflex X-ray powder diffractometer
(Danvers, MA) using Cu Ka radiation (l¼ 1.54 Å), a
tube voltage of 30 kV, and a tube current of 15 mA.
The intensities were measured at 2u values from 28 to
408 at a continuous scan rate of 2.58min1. Results
were compared to diffraction patterns reported in
literature or calculated from crystal structures
reported in the Cambridge Structural Database
(CSD).
High-Performance Liquid Chromatography (HPLC)
Solution concentrations of THP and CTA were
analyzed by Waters HPLC (Milford, MA) equipped
with a UV/vis spectrometer detector. A C18 Atlantis
column (5mm, 4.6 mm 250 mm; Waters) at ambient
temperature was used to separate THP and CTA. A
gradient method, starting with 40% methanol and
0.1% trifluoroacetic acid in water and increasing
methanol to 95%, was used with a flow rate of
1 mL min1. Sample injection volume was 20mL.
Absorbance of the THP and CTA was monitored
between 210 and 300 nm. Empower software from
Waters was used to collect and process the data. All
concentrations are reported in molality (moles solute/
kilogram solvent) unless otherwise indicated.RESULTS
Effect of Coformer Concentration on THP–CTA
Cocrystal Hydrate Stability
Cocrystal hydrate stability was initially investigated
by suspension equilibration in aqueous solutions of
CTA of several concentrations. Cocrystal hydrate
stability and conversions were found to be dependent
on coformer concentration as summarized in Figure 1,
and as indicated by XRPD patterns of solid phases
(Supporting Information). THP–CTA hydrate was
found to be stable at CTA concentrations between
2.39 and 6.80 m. Cocrystal hydrate transformed to
THP hydrate at CTA concentrations below 1.62 m,
and to THP–CTA cocrystal anhydrous above 7.31 m.
Thus, coformer solution concentration not only
determines conversions between cocrystal and com-
ponents but between anhydrous and hydrated
cocrystal phases.URNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 2010
Figure 1. Dependence of theophylline–citric acid co-
crystal hydrate stability on the concentration of citric acid
in solution.
3980 JAYASANKAR, ROY, AND RODRÍGUEZ-HORNEDOEutectic Points and Phase Diagram of THP–CTA
Cocrystals
Cocrystal eutectic points or transition concentrations,
where two solid phases coexist in equilibrium with
solution, have been shown to be key indicators of
cocrystal stability.1,37,42 Results presented above for
THP–CTA cocrystals suggest that this system exhi-
bits three eutectic points (E1, E2, and E3). Solution
concentrations of cocrystal components at the eutectic
points and the associated solid phase equilibria were
measured and are presented in Table 1. The solid
phases in equilibrium with solution at E1, E2, and E3
were found to be drug hydrate/cocrystal hydrate,
cocrystal hydrate/anhydrous cocrystal, and anhy-
drous cocrystal/coformer hydrate, respectively.
Table 1 shows that (THP)eu decreases as (CTA)eu
increases from eutectic points E1 to E2. In the region
above E1 and below E2, cocrystal hydrate is the
thermodynamically stable phase. Therefore, its solu-
bility, represented by the THP concentrations,
decreases with increasing coformer concentration.
Above E2 and below E3, anhydrous cocrystal is the
thermodynamically stable phase. Coformer solution
composition is thus controlling cocrystal solubility as
well as its hydrated state.
A phase solubility diagram (PSD) generated from
eutectic point measurements is shown in Figure 2.
This plot indicates stability domains of solid phases
and associated solution concentrations. The figure
was constructed from experimentally measured
eutectic concentrations and cocrystal solubility
dependence on coformer concentration as previously
reported for other systems.1,24,37 In addition to
transformation between cocrystal hydrate/anhy-
drous, there are also regions where cocrystal trans-






aConcentrations are mean standard deviation.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 2010THP hydrate solubility is indicated by the line a-E1
and CTA solubility by b-E3. Solubility of both
components is observed to increase compared to pure
solvent.
Solution Water Activity and THP–CTA Cocrystal
Stability
Conversion of hydrated to anhydrous cocrystal at
coformer concentrations above E2 is explained by the
effect of coformer concentration on water activity, a
factor well known to determine the stability of
pharmaceutical hydrates.13,14,20–23 Water activity of
solutions at eutectic points E1 and E2 and of solution
compositions in between E1 and E3 were measured
and are plotted in Figure 3. Water activities of THP/
CTA solutions are slightly lower (3%) than those
reported in the literature for aqueous solutions of
CTA.34,43–45 This may be due to the presence of THP
as well as differences in the methods used to measure
water activity.
XRPD patterns of solid phases at equilibrium
(Supporting Information) corresponding to solution
concentrations and water activities presented in
Figure 3 demonstrate that the critical water activity
where hydrated and anhydrous cocrystals are in
equilibrium is 0.8. Above this aw anhydrous cocrystal
converted to its hydrated form and below this value
the reverse conversion was observed.
Besides coformer, other excipients such as sugars
used in pharmaceutical formulations can also lower
the water activity of solutions. Fructose is reported to
lower the water activity of aqueous solutions to 0.64
at saturation.35,46 This value is below the critical aw
for the anhydrous/hydrate THP–CTA cocrystal. Thus,
varying fructose concentrations in cocrystal suspen-
sions can lead to conversions between anhydrous and
hydrated forms of the cocrystal.
Figure 3 shows the effect of fructose on aw and
cocrystal hydrate stability in aqueous THP/CTA
solutions. Since cocrystal hydrate transforms to
crystalline drug hydrate in water without CTA, the
effect of fructose on cocrystal hydrate stability was
investigated in coformer solutions where cocrystal
hydrate is stable. XRPD patterns of solid phases at
equilibrium (Supporting Information) demonstrate
that as aw is lowered from 0.84 to 0.79, by addition of
fructose to 6.05 m CTA solutions, cocrystal hydrate
converts to its anhydrous form. This also correspondsquilibrium With THP/CTA Aqueous Solutions at 258C
)eu
a (m) Solid Phases at Equilibrium
0.05 Theophylline hydrate, cocrystal hydrate
0.01 Cocrystal hydrate, anhydrous cocrystal
0.20 Anhydrous cocrystal, citric acid hydrate
DOI 10.1002/jps
Figure 2. Phase solubility diagram of theophylline–citric
acid cocrystals showing the stability domains and solubility
dependence on coformer concentrations for the different
solid phases. E1, E2, and E3 correspond to eutectic points.
‘‘a’’ and ‘‘b’’ represent the aqueous solubilities of theophyl-
line hydrate and citric acid hydrate as reported in the
literature.33,34,50 Lines through a, E1, E2, E3, and b are
drawn based on the behavior of the cocrystal solubility
dependence on coformer for other cocrystal systems. The
stability domains of crystalline phases are: a-E1: theophyl-
line hydrate, E1E2: cocrystal hydrate, E2E3: anhydrous
cocrystal and bc3: citric acid hydrate.
Figure 3. Effect of water activity on THP–CTA cocrystal
hydrate/anhydrous stability. Line indicates the critical
water activity for the anhydrous/hydrate THP–CTA cocrys-
tal equilibrium. Water activity as a function of citric acid
concentration in (a) citric acid aqueous solutions (&43 *34
^44 D45,51), (b) theophylline and citric acid aqueous solu-
tions at eutectic points: E1 in equilibrium with THP
hydrate/cocrystal hydrate, and E2 in equilibrium with
cocrystal hydrate/anhydrous ( ), and in equilibrium with
cocrystal hydrate or anhydrous ( ), and (c) in solutions of
fructose at constant citric acid concentration in equilibrium
with cocrystal hydrate or anhydrous ( ).
DOI 10.1002/jps JO
TRANSFORMATION PATHWAYS OF COCRYSTAL HYDRATES 3981to a decrease in eutectic concentrations at E2 as
observed for (CTA)eu, from 7.31 to 6.05 m. Thus, the
main factor controlling the cocrystal hydrate to
anhydrous stability is aw, which in this case is
modulated by both coformer and sugar.
RH-Dependent Stability of THP–CTA Cocrystal
The stability of THP–CTA cocrystals was evaluated at
85% and 98% RH for 5 months. Both anhydrous and
hydrated cocrystals were found to be stable at 85%
RH whereas at 98% RH both cocrystals converted to
THP hydrate. The critical aw of 0.8 determined by
suspension equilibration suggests that conversion by
vapor phase equilibration may be kinetically con-
trolled. Similar behavior by vapor and suspension
equilibration has been shown for THP hydrate and
anhydrous.13,17,22,47
The cocrystal hydrate has been reported to be
stable at 98% RH, however, the length of storage was
only 1 week.12 The reasons for this difference in
behavior at 98% RH may be explained by longer
storage times required for conversion and/or by the
existence of coformer as an impurity in cocrystal
samples. We observed deliquescence at 98% RH for
both cocrystal phases with significant water uptake at
5 months (>70%, w/w). At 85% RH, the water uptake
was in the range of 4–6%. DSC analysis of several
cocrystal samples in our studies revealed coformer
impurity between 0.5% and 5% (w/w). CTA is
deliquescent and trace levels in cocrystal samples
stored at or above its deliquescent RH could lead to
conversions via solution phase. It is also noted that
caffeine–CTA cocrystal has been reported to deli-
quesce at 98% and convert to caffeine hydrate in 1
week.12
Moisture Sorption of Cocrystal Components THP/CTA
and RH-Dependent Transformations
Results from the above studies show that solution
composition and corresponding coformer/water activ-
ities determine transformation pathways of cocrys-
tals to hydrated, anhydrous cocrystal phases or to
hydrated phases of components. Since CTA is a water
soluble, deliquescent coformer, it is possible for
moisture sorption of mixtures to cause phase changes.
RH-dependent behavior of equimolar mixtures of
THP/CTA summarized in Figure 4 was studied by
XRPD and Raman spectroscopy (Supporting Informa-
tion). Formation of cocrystal was found to occur at
all RH conditions studied, but the pathways were
dependent on RH. The critical aw for THP hydrate has
been reported as 0.25 at 258C 13 and 0.6 at 228C.22
Anhydrous cocrystal was formed initially at all RH
values, and converted to hydrated cocrystal and THP
hydrate as RH values increased above the CTA DRH
of 78–79%.33–35 Anhydrous cocrystal was formedURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 2010
Figure 4. Transformation pathways of equimolar mixtures of anhydrous THP and
anhydrous CTA exposed to different RH. Total storage times are indicated.
3982 JAYASANKAR, ROY, AND RODRÍGUEZ-HORNEDOwithin weeks at 75% RH and within a few hours at
98% RH.
Initial formation of anhydrous cocrystal and sub-
sequent conversion to other phases is explained by the
phase equilibrium dependence on solution composi-
tion and aw. As shown by eutectic points and PSD
(Fig. 3 and Tab. 1), conversion of a mixture of
cocrystal components to anhydrous cocrystal!hy-
hydrated cocrystal!THP hydrate is associated with
high initial CTA concentrations (between E3 and E2)
and further dilution by moisture uptake leading to
conditions where hydrated cocrystal (between E2 and
E1) or THP hydrate (E1 and below) are in equilibrium.
Cocrystal component concentrations and activities
are higher in the earlier stages of moisture uptake
(small volumes of sorbed moisture) and decrease as
the moisture sorption and deliquescence proceed
(larger volumes of moisture will be sorbed at higher
RH). Thus the interplay of water and component
activities in the deliquesced liquid determines the
conversions between component and cocrystal
phases.
Water Activity and Stability of CBZ–4ABA Cocrystals
Previous studies from our laboratory have shown that
the hydrated CBZ–4ABA cocrystal is unstable in pure
water and transforms to carbamazepine dihydrate.
The eutectic points for the equilibrium between CBZ–
4ABA hydrate and CBZ dihydrate as a function of
coformer concentration and pH were also reported.4
The hydrated cocrystal was found to be stable in
water saturated with 4ABA. Therefore in the present
study, the influence of aw on the stability of 2:1 CBZ–JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 20104ABA anhydrous/hydrated cocrystals was measured
in water/acetonitrile solutions. XRPD patterns of
solid phases at equilibrium (Supporting Information)
demonstrate that anhydrous cocrystal is stable at
aw 0.26 and cocrystal hydrate is stable at aw	 0.30.
Thus, the critical water activity above which the
cocrystal hydrate is thermodynamically stable is
0.26–0.30.
Vapor phase equilibration studies showed that both
anhydrous and hydrated cocrystals resist conversion
under conditions far from the equilibrium aw
measured by suspension. Anhydrous cocrystal stored
at 43% RH (5 months) and 89% RH (1 month), and
hydrated cocrystal stored at 0% RH (1 month) and
13% RH (5 months) did not show evidence of
conversion by XRPD analysis.DISCUSSION
Cocrystals can exist as anhydrous and hydrated
forms and convert to (a) hydrated or anhydrous
components in addition to (b) hydrated or anhydrous
cocrystal.4,8–12 Results from this study show that
cocrystal hydrate/anhydrous stability is dependent on
coformer concentration indicating that both coformer
and water activities determine phase stability.
Depending on coformer concentration, cocrystal
hydrate can transform to crystalline drug or anhy-
drous cocrystal. Conversions between anhydrous and
hydrated cocrystals occur when coformer and/or
excipients modulate water activity of solutions as
demonstrated for THP–CTA cocrystal hydrate/anhy-DOI 10.1002/jps
Figure 5. Triangular phase diagram showing the stabi-
lity domains for anhydrous and hydrated cocrystals with
coformers that modulate the water activity. Points ‘‘a’’ and
‘‘b’’ correspond to API hydrate and coformer hydrate
aqueous solubility. E1, E2, and E3 represent eutectic points.
Curves aE1, E1E2, E2E3, and E3b represent the solubilities
of crystalline drug hydrate, cocrystal hydrate, anhydrous
cocrystal, and hydrated coformer, respectively. Stability
regions for the crystalline phases are: 1, crystalline drug
hydrate; 2, cocrystal hydrate; 3, anhydrous cocrystal; 4,
coformer hydrate; 5, crystalline drug hydrate/cocrystal
hydrate; 6, anhydrous/hydrated cocrystals; 7, anhydrous
cocrystal/hydrated coformer. Pathway R represents the
transformation occurring by reaction crystallization or
deliquescence of solid mixtures during storage.
TRANSFORMATION PATHWAYS OF COCRYSTAL HYDRATES 3983drous. CBZ–4ABA did not exhibit such solution-
mediated conversion since 4ABA has low-aqueous
solubility with little effect on water activity. The aw of
saturated aqueous 4ABA (aw¼ 0.98) is much higher
than the critical aw of CBZ–4ABA hydrate (aw¼ 0.26–
0.30).
Cocrystals of highly water soluble coformers, such
as THP–CTA, are predisposed to conversions due to
moisture uptake and deliquescence of the coformer.
This behavior may explain the RH-dependent stabi-
lity reported for cocrystals of THP and caffeine with a
series of carboxylic acids (malonic, maleic, glutaric, D-
malic, malic, D-tartaric, and tartaric).8,11,25 Resis-
tance to conversion to hydrated drug at 98% RH
appears to be correlated with the solubility and
hygroscopicity of the coformers. The coformer with
the lowest solubility and hygroscopicity, oxalic acid
(S¼ 1.3 m, DRH¼ 98%),48 exhibited the best cocrystal
stability at 98% RH. The most soluble and hygro-
scopic coformer, D-malic acid (S¼ 19.5 m,
DRH¼ 56%),48 was the only cocrystal unstable at
75% RH. Cocrystals with malonic (S¼ 15.3 m,
DRH¼ 73%),48 glutaric (S¼ 10.7 m, DRH¼ 88%),48
and D-malic converted to the hydrated drug at 98%
RH. This behavior is paralleled by cocrystals com-
posed of the racemic versus chiral coformers.25 The
latter have higher solubility and hygroscopicity than
the racemic forms. As with our results for THP–CTA
cocrystal stability dependence on RH, it is not clear
whether the observed instability reflects that of the
cocrystal or is due to coformer impurities. Trace levels
of coformer undetected by XRPD can significantly
affect the stability of cocrystals when the coformer
DRH is at or below ambient RH.
Eutectic points are key parameters to identify
cocrystal stability domains.1,37,42 From the eutectic
concentrations, PSD showing the reactant solution
concentrations at equilibrium with the different solid
phases as well as the cocrystal stability domains can
be plotted as shown in Figure 3.24,37 Alternatively,
the stability domains can also be represented on a
triangular phase diagram (TPD) that shows the total
composition of the system, including the solid and
liquid phases.10,20,24,26 Figure 5 shows a schematic
TPD where the coformer modulates the water activity
similar to THP/CTA/water system. Given the large
differences in drug and coformer solubilities in the
THP/CTA/water system, a hypothetical ternary
system is presented for visual clarity to qualitatively
show the transformation pathways by moisture
sorption or when solid phases are in contact with
solutions.
Transformation pathways and crystallization out-
comes can be predicted from the phase diagram as
represented by the pathway ‘‘R’’ for deliquescence of a
component in a solid mixture. During deliquescence,
supersaturation with respect to cocrystal is generatedDOI 10.1002/jps JOby nonequivalent cocrystal component concentrations
in the deliquesced solution. As deliquescence begins,
the sorbed water is saturated with coformer (gen-
erally the more soluble component).41,49 Under these
conditions, the anhydrous cocrystal is the least
soluble and most stable phase. The dissolution of
drug in this solution therefore generates super-
saturation with respect to anhydrous cocrystal.
Further transformation of anhydrous cocrystal to
cocrystal hydrate will occur when supersaturation
with respect to cocrystal hydrate is generated. This is
achieved when the coformer concentration falls below
that corresponding to the eutectic point E2.
The concentration of the coformer in a deliquesced
solution depends on the RH. At the DRH, the
deliquesced solution remains saturated with the
coformer. However, at higher RH (RH>DRH),
increased levels of water uptake lead to coformer
dilution in the deliquesced solution thereby affecting
cocrystal stability. Coformer dilution at high RH
explains the observed transformation pathway in
THP/CTA mixtures at 85% and 98% RH.
A previous study from our laboratory showed that
cocrystals of CBZ–nicotinamide, caffeine and THP
with oxalic, mandelic, malonic, and glutaric acids
form, in mixtures of coformer and drug, as a result of
coformer deliquescence.41 Although these cocrystalsURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 9, SEPTEMBER 2010
3984 JAYASANKAR, ROY, AND RODRÍGUEZ-HORNEDOconvert to drug hydrate in pure water, their forma-
tion in mixtures of components was explained by
dissolution of reactants in the deliquesced liquid
phase leading to nonstoichiometric solution composi-
tions and supersaturation with respect to cocrystal.
The critical aw of CBZ–4ABA and THP–CTA
hydrates is different from those of the drug hydrates.
The critical aw for CBZ and THP hydrates is reported
as 0.64–0.6520,21 and 0.25–0.6,13,22 respectively. The
critical aw is an indicator of the thermodynamic
stability of hydrates, with lower values implying
greater tendency for hydration. Differences in the
critical water activities of drug and cocrystal hydrates
may be due to differences in the crystal structure,
hydrogen bond interactions between water, drug,
and/or coformer, as well as differences in solubility
and free energy of these materials.CONCLUSIONS
Coformers, excipients, and cosolvents that modulate
the water activity of solutions can affect cocrystal
hydrate/anhydrous stability and induce transforma-
tion to or from anhydrous cocrystal. This is shown for
THP–CTA and CBZ–4-ABA cocrystal hydrates and
anhydrous forms. Cocrystal stability is determined by
both water and coformer activities and can be
evaluated by suspension equilibration studies by
measurement of both cocrystal component concentra-
tions at equilibrium. Key parameters to identify
anhydrous and hydrated cocrystal stability domains
are eutectic concentrations and critical water activity.
Vapor phase equilibration studies should take into
account the purity of cocrystal phases since the
presence of water-soluble coformers as trace level
impurities are expected to alter the observed hygro-
scopic behavior of cocrystals.ACKNOWLEDGMENTS
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